GLG News Analyses of the following article:

Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study

view article

Published at: www.thelancet.com

Kelly Close, President

Kelly ClosePresidentClose Concerns What is a GLG Leader?|The Gerson Lehrman Group&reg; (GLG) Leader Program<sup>SM</sup> is our premium Member Program<sup>SM</sup>. Those identified as GLG Leaders are in the top 5% of GLG CouncilRank and have an exclusivity agreement with GLG.

Novo Nordisk's Liraglutide Wins in Obesity Too

October 29, 2009

Results from a 20-week study of the GLP-1 analog liraglutide in obese and overweight patients were recently published in The Lancet. In the trial, 564 patients were randomized to one of six groups: orlistat (120 mg, 3 times daily), placebo, and liraglutide 1.2 mg, 1.8 mg, 2.4 mg, or 3.0 mg. The trial involved a three-week screening period,a two-week run-in period, a 20-week double blind study period, and a 84-week open label follow up.

Subscribe to Updates

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines

Work for one of the world's leading organizations? Get started now.

Get Intelligently Connected
with the world's leading experts

GLG's 850+ Clients Include:

More than 70% of the world's leading
mutual funds
15 of the leading 20
global banks
9 of the leading 10
global private equity firms
5 of the leading 10
AmLaw firms
Fortune 500® Companies
in nearly every industry sector, including pharmaceuticals, insurance, chemicals, energy and computer software